Diaceutics PLC (AIM:DXRX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 172.74M +26.0% |
| Revenue (ttm) | 41.33M +20.1% |
| Net Income | -271.00K |
| EPS | -0.00 |
| Shares Out | 84.89M |
| PE Ratio | n/a |
| Forward PE | 238.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 575,986 |
| Open | 202.55 |
| Previous Close | 202.50 |
| Day's Range | 201.19 - 205.00 |
| 52-Week Range | 125.00 - 207.00 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 213.00 (+4.67%) |
| Earnings Date | Sep 22, 2026 |
About Diaceutics
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending;... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DXRX stock is "Strong Buy." The 12-month stock price target is 213p, which is an increase of 4.67% from the latest price.
News
Half Year 2026 Diaceutics PLC Analyst Presentation Transcript
Half Year 2026 Diaceutics PLC Analyst Presentation Transcript
Diaceutics accelerates growth on precision medicine demand
Diaceutics is entering the second half of 2026 with growing momentum, after a sharp increase in recurring revenue.
Diaceutics Quarterly report: H1 2026
Diaceutics has published its H1 2026 quarterly earnings report on September 22, 2026.
Diaceutics Slides: H1 2026
Diaceutics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 22, 2026.
Diaceutics Earnings release: H1 2026
Diaceutics released its H1 2026 earnings on July 29, 2026, summarizing the period's financial results.
Diaceutics Earnings Call Transcript: H2 2025
Revenue grew 20% year-over-year with a return to profitability and strong adjusted EBITDA margin, despite challenging pharma market conditions. Strategic investments in data and expansion into new therapeutic areas support future growth and margin expansion.
Diaceutics Annual report: H2 2025
Diaceutics has published its H2 2025 annual report on May 26, 2026.
Diaceutics Annual report: H2 2025
Diaceutics has published its H2 2025 annual report on May 26, 2026.
Diaceutics Slides: H2 2025
Diaceutics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on May 26, 2026.
Diaceutics Slides: Corporate presentation
Diaceutics has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Diaceutics Earnings release: Q4 2025
Diaceutics released its Q4 2025 earnings on January 15, 2026, summarizing the period's financial results.
Diaceutics price target raised to 195 GBp from 165 GBp at RBC Capital
RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics (DIUXF) to 195 GBp from 165 GBp and keeps an Outperform rating on the shares. Published first on…
Diaceutics price target raised to 165 GBp from 145 GBp at RBC Capital
RBC Capital analyst Natalia Webster raised the firm’s price target on Diaceutics to 165 GBp from 145 GBp and keeps an Outperform rating on the shares.
Diaceutics initiated with an Outperform at RBC Capital
RBC Capital analyst Natalia Webster initiated coverage of Diaceutics with an Outperform rating and 145 GBp price target. The analyst says the company’s proprietary data and analytics platform enable i...